Bioventus (BVS) EBITDA (2020 - 2026)

Bioventus' EBITDA history runs 7 years deep, the most recent figure standing at $8.4 million for Q1 2026.

• Quarterly EBITDA rose 72.85% year-over-year to $8.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.5 million (up 477.09% YoY) and the FY2025 annual result came in at $54.0 million, up 455.22% from the prior year.
• EBITDA was $8.4 million for Q1 2026 at Bioventus, down from $19.5 million in the prior quarter.
• Across five years, EBITDA topped out at $19.5 million in Q4 2025 and bottomed at -$126.8 million in Q4 2022.
• A 5-year average of -$11.9 million and a median of $3.6 million in 2024 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2022 — EBITDA sank 12014.52% — and 2024, when it jumped 561.2%.
• Bioventus' EBITDA stood at -$15.6 million in 2022, then soared by 107.45% to $1.2 million in 2023, then soared by 561.2% to $7.7 million in 2024, then jumped by 152.97% to $19.5 million in 2025, then tumbled by 56.81% to $8.4 million in 2026.
• Business Quant data shows BVS's EBITDA at $8.4 million in Q1 2026, $19.5 million in Q4 2025, and $11.3 million in Q3 2025.